• 20% of patients tested positive for pathogens missed by routine tests
• 78% of detected pathogens are often missed by standard diagnostics
• 58% of tests showed abnormal microbiome results

Microba Life Sciences has announced compelling new data demonstrating the ability of its MetaPanel test to identify clinically significant pathogens that are often missed by standard diagnostic approaches, guide treatment, and achieve symptom resolution. An analysis of 889 MetaPanel reports from patients with long-term gastrointestinal (GI) symptoms found that 20% tested positive for a pathogen, including 2.4% positive for multiple pathogens. Importantly, the majority (approximately 78%) of these positive results were for pathogens often missed by routine tests used in Australia, such as traditional PCR panels and microscopy culture sensitivity. MetaPanel's broader target set of 115 pathogens and virulence factors allows for the detection of the long tail of clinically significant pathogens frequently missed by routine testing. An additional 58.3% of tests showed abnormal microbiome results, which may be targeted through nutritional and/or lifestyle interventions, and support reflex or referral to a MetaXplore test for further investigation. In an independent study of 42 patients with chronic diarrhoea, 19% tested positive for a pathogen with MetaPanel, and all cases (100%) who were treated using the expert pathologist report recommendation experienced complete symptom resolution. These results demonstrate that MetaPanel is a powerful new tool for clinicians managing complex gastrointestinal cases, enabling them to uncover the hidden infectious causes of persistent GI symptoms and deliver targeted, effective treatment.

These encouraging results demonstrate the ability of MetaPanel to detect clinically significant pathogens that are missed by standard pathology tests. The symptom resolution observed in all treated patients underscores its potential to transform outcomes for patients with chronic GI conditions.